INTRODUCTION
Neurodegenerative diseases, including Parkinson's, Alzheimer's, and Huntington diseases, are defined by their progressive loss of structure or function of anatomically defined groups of neurons. Neurodegenerative diseases affecting children are at the most severe end of the spectrum, often affecting key regulatory enzymes in neuronal function and energy metabolism. These diseases include lysosomal, peroxisomal, and mitochondrial defects such as Tay-Sachs, Zellweger, and Leigh syndromes, respectively, resulting in a host of specific early-onset neurodegenerative phenotypes. Although significant progress has been made in the underlying pathogenesis for both the adult and pediatric forms of disease, treatment currently remains out of reach for most patients (Thompson and Levitt, 2010) .
Much of cerebellar growth occurs after birth (Rakic and Sidman, 1970) , and therefore, early onset degeneration is impossible to differentiate from hypoplasia. Pontocerebellar hypoplasia (PCH) represents a group of rare inherited progressive neurodegenerative disorders with prenatal onset and up to seven subtypes with clear evidence for time-dependent loss of brain parenchyma (Barth, 1993; Maricich et al., 2011; Namavar et al., 2011) . The defect is observed at birth, and thus the condition was initially considered as a hypoplasia, but degenerative features are fully documented (Namavar et al., 2011) . Additional features of PCH include progressive microcephaly, defects of the corpus callosum, and clinical features of swallowing and feeding difficulties along with limb spasticity. Death usually results from chronic medical complications within the first 10 years of life, and no treatments exist.
Mutations in the evolutionarily conserved transfer RNA (tRNA) splicing endonuclease (TSEN) complex, including TSEN54, TSEN34, and TSEN2, were identified in some PCH patients to date (Budde et al., 2008) , presumably implicating a protein synthetic defect in the disorder. In addition, PCH is associated with mutations in the CHMP1A gene, a regulator of BMI1-INK4A (Mochida et al., 2012) , and in the RNA exosome component gene EXOSC3 in a subvariant of PCH involving spinal motor neuron degeneration (Wan et al., 2012) . Thus, a host of pathways regulating RNA biology, polycomb signaling, and protein synthesis interplay in the etiology of PCH.
Purine nucleotide metabolism is one of the most-studied processes in biology, critical for synthesis of ATP and guanosine triphosphate (GTP) to meet requirements both for energy production and nucleic acid synthesis (Nyhan, 2005) . The de novo purine synthetic pathway initiates with ribose-5-phosphate conversion to inosine monophosphate (IMP), which is then converted to either ATP or GTP, depending upon cellular requirements. The salvage pathway converts hypoxanthine and guanine to IMP and GMP, respectively, through the enzyme hypoxanthineguanine phosphoribosyltransferase (HGPRT) (see Table S1 for abbreviations, available online), which is mutated in Lesch-Nyhan syndrome. Adenine salvage to AMP occurs through adenine phosphoribosyltransferase, which is mutated in some patients with renal failure. Although these fundamental steps are understood at the biochemical level, the mechanisms of cellular vulnerability to purine toxicity are not well understood, and other than in Lesch-Nyhan syndrome, neurological consequences are rarely described (Camici et al., 2010) .
In this study, we identify AMPD2 as necessary for guanine nucleotide biosynthesis and protein translation. Our data provide evidence that AMP deaminase activity is critical during neurogenesis. We describe a distinct type of PCH in five families caused by a defect in this enzymatic step that can be overcome at the cellular level by administration of a purine nucleotide precursor.
RESULTS

Identification of AMPD2 Mutations in a Distinct
Pontocerebellar Hypoplasia-like Syndrome In order to identify additional causes of pontocerebellar hypoplasia, we recruited a cohort of 30 probands and their families with a presumptive diagnosis of PCH. We previously excluded cases with overlapping conditions such as Walker-Warburg syndrome, cortical pachygyria, or evidence of altered metabolism such as elevations of serum lactate or abnormal peaks on standard clinical serum tandem mass spectroscopy. From these 30 families, 23 had documented parental consanguinity (first or second cousin marriages), and 21 displayed more than one affected member, which is consistent with the recessive mode of inheritance for PCH. Of the 30 probands, most had evidence of mild to moderate microcephaly, hypotonia/spasticity of the limbs, and progressive contractures. All patients had the classical MRI features of PCH (cerebellum and pontine size reduced at least by 50%) and were enrolled in this institutional review board (IRB)-approved genetic study.
Exome sequence was generated in 68 individuals from either two probands (from multiplex families) or both parents and affected (from simplex families) and interrogated for homozygous, compound heterozygous, and de novo sequence changes and compared with our in-house database from 1,500 Middle Eastern exomes. One family each had a demonstrable mutation in EXOSC3 and TSEN2, and three families had mutations in TSEN54, all of which were predicted to be damaging to protein function and segregated according to a strictly recessive mode of inheritance. The results validated our recruitment strategy for PCH and suggested additional causes in the remaining families. Although several potentially mutated genes emerged from this screen, one was recurrent-the adenosine monophosphate deaminase-2 gene (AMPD2).
AMPD2 encodes one of three known AMP deaminase homologs, which converts AMP to IMP. In total, five unique homozygous mutations in AMPD2 were independently identified in this cohort ( Figures 1A and 1B) , including two premature stop codons: one in family PCH-1022 and the other within the most significant linkage interval in family PCH-1298 ( Figure S1A ). The other three mutations occur in a helixes, alter the charge, polarity, or helical propensity of highly conserved amino acids ( Figures 1C and S1B ) (Pace and Scholtz, 1998) , and are predicted to disrupt key hydrogen bonds involved in protein integrity ( Figure S1B ) modeled on the solved structure of Arabidopsis AMP deaminase (Han et al., 2006) . Sanger sequencing confirmed that all five mutations segregated according to a strictly recessive model of inheritance with full penetrance (Figure S1C ). These variants were not present in our in-house exome sequences of an additional 1,500 individuals or in publically available SNP databases. The results suggest that AMPD2 loss results in PCH.
Comparing brain MRI features among the five patients, we retrospectively identified a pathognomonic structural brain anomaly, which we propose as PCH type 9, that is distinct from other patients with PCH. In all patients, there was hypoplasia/atrophy of the cerebellum, with a fluid-filled posterior fossa (mega cisterna magna) and flattening of the ventral part of the pons. The unique finding was present on axial images in which the brainstem takes on a ''figure 8'' appearance, with relative preservation of the cerebellar vermis. There was also generalized atrophy of the cerebral cortex and severe corpus callosum hypoplasia ( Figures 1A and S1D and Table S2 ), but other organs were spared.
AMPD2 Is a Functional Ortholog of Yeast AMD1 Gene AMPD2 is one of three paralogs in mammals mediating the conversion of AMP to IMP (Bausch-Jurken et al., 1992) , which are all branched from a single ancestral AMP Deaminase gene common with AMD1 (Figure 2A ), the unique AMP deaminase in Saccharomyces cerevisiae (Meyer et al., 1989) . Human AMPD2 has the most sequence similarity to AMD1 (53% identity and 69% similarity over 623 amino acids), as compared with AMPD1 and 3. Individuals with AMPD1 homozygous mutations display Myoadenylate deaminase deficiency (MIM+102770), which is possibly the most prevalent genetic disease in humans. However, only a small percent of homozygous-deficient individuals show symptoms, including exercise-stress-induced accumulation of AMP with resultant muscle weakness and cramping (Fishbein et al., 1978) . AMPD3 shows homozygous inactivating mutations in healthy individuals (Ogasawara et al., 1987) , with increased adenosine nucleotide levels in erythrocytes (Mendelian Inheritance in Man [MIM]: 612874). RT-PCR analysis of the gene family in human tissue shows expression of AMPD1 predominantly restricted to muscle but shows AMPD2 and -3 with widespread expression ( Figure S2A ).
To determine whether human AMPD2 is a functional ortholog of yeast AMD1, we expressed AMPD2 in the yeast amd1 mutant (Jones, 1982) . As previously reported (Saint-Marc et al., 2009) , this mutant shows a strong germination and/or growth of spore phenotype in the presence of adenine, which is rescued by forced expression of yeast AMD1 under the tetracycline response element ( Figure S2B ). Presumably, the presence of exogenous adenine effectively stresses the cells, resulting in further accumulation of adenosine nucleotides. Using the same vector system, we found that human AMPD2 complementary DNA (cDNA) showed near-complete rescue of growth ( Figure 2B ).
AMPD2 Mutations Are Deleterious for Protein Function
We next expressed in the yeast amd1 mutant each of the identified patient mutations introduced in the AMD1 gene in order to test for altered activity. In the presence of doxycycline, AMD1 rescued the amd1 phenotype, but mutated versions of the yeast gene failed to complement the growth defect ( Figure 2C ). We conclude that the patient mutations represent null alleles. Some residual activity was, however, observed in conditions of overexpression for corresponding mutations E778D and R674H ( Figure S2C ), suggesting that some patient missense mutations may maintain minimal residual activity.
In order to determine the effect of mutations on protein function in mammalian cells at physiological expression levels, we obtained skin fibroblast cultures from patients and one unaffected parent in three different families. AMPD2 protein was nearly completely absent in patient cells ( Figure 2D ). By the assessment of AMP deaminase activity from lysed patient cells Figure S1 and Table S2. in the presence of exogenous AMP (Kirkwood et al., 2012) , we found reduction of 80%-90% of activity ( Figure 2E ), suggesting no compensatory effect by AMPD3 expression in these cells ( Figure S2D ). We conclude that patient cells show severe reductions in AMPD2 levels and AMP deaminase activity.
Survival Is Compromised in Challenged AMPD2
Mutant Cells
The near-complete absence of enzymatic AMP deaminase activity prompted a search for a phenotype in patient cells. However, we found that cell growth and survival of fibroblasts were unaffected under basal growth conditions and found no evidence of altered purine nucleotide levels (Figures S3A and S3B) . The amd1 yeast mutant shows growth restriction only in the presence of exogenous adenine, which feeds directly into AMP through APRT (Alfonzo et al., 1997) . Thus, we considered that addition of exogenous purines to these cells might uncover relevant phenotypes. We utilized adenosine, which is both bioavailable and feeds into AMP through adenosine kinase ( Figure 3A ), and found a dose-dependent effect on cell survival in patient fibroblasts in the range of 50-500 mM concentrations, dropping to about half of untreated survival rates. Cells from unaffected family members showed no effect of adenosine at these concentrations ( Figures 3B and 3C ). We conclude that, like the yeast amd1 mutant, metabolic stress is required to uncover phenotypic consequences in AMPD2 mutant cells.
To study the mechanism of human neuronal vulnerability in AMPD2 mutants, we generated induced pluripotent stem cells (iPSCs) from families PCH-1298 and PCH-1236 and from both affected (AMPD2 homozygous mutants) and unaffected (heterozygous controls). Because there is generalized brain affection in PCH9 patients (including microcephaly and corpus callosum (E) Reduced AMP deaminase activity in affected (A) compared with related unaffected (U) fibroblasts, measured by standard colorimetric AMP deaminase assay. Top: blue intensity represents relative activity. Bottom: quantification of activity ± SD for three independent experiments. *p < 0.05 and **p < 0.005; Student's t test. See also Figure S2. involvement), we reasoned that standard neural-induction-protocol-derived cells might capture the neuronal vulnerability observed in patients. We demonstrated expression of pluripotency markers, differentiation to three germ layers after embryoid body formation, and generation of neural progenitor cells (NPCs) using standard methods of derivation (Chambers et al., 2009) (Figures 3D and S3C) . Growth rates and purine nucleotide levels were indistinguishable in standard culture medium (Figures S3D and S3E) , as were survival of neural progenitor cells. We confirmed the absence of AMPD2 and a nearly complete loss of AMP deaminase activity ( Figure S3F ).
Standard NPC medium lacks adenosine (Table S3) , whereas concentrations from 20 nM to 300 mM are well documented in mammalian brain (Rathbone et al., 1999 ). Thus, we tested a range of adenosine concentrations and found that the survival of AMPD2 mutant, but not control NPCs, dropped considerably at concentration as low as 5 mM ( Figures 3E and 3F) , which is an order of magnitude more sensitive than the isogenic patient fibroblasts. To test for specificity of the effect, we transduced affected NPCs with either AMPD2 or a fluorescent tag and found restoration of survival specifically following AMPD2 transduction ( Figure S3G) . Thus, the addition of physiological adenosine concentrations to the AMPD2 mutant cells can recapitulate the neural-specific defect observed in patients, providing a model to further explore the underlying mechanisms leading to neurodegeneration. (C) Bright-field images for affected PCH-1298 and PCH-1236 fibroblasts in standard medium or 50 mM adenosine-supplemented medium, documenting a modest drop in survival. (D) Bright-field images for PCH-1298 and PCH-1236 unaffected and affected derived iPSC and neural rosettes (NR). PAX6 (green) and NESTIN (red) immunostaining in neural progenitor cells (NPCs), corresponding to one unaffected and one affected clone per family. (E) Survival rates of unaffected and affected NPCs from families PCH-1298 and PCH-1236, cultured with escalating adenosine concentrations for 72 hr, which show a 10-fold increase in sensitivity to adenosine concentrations of NPCs compared with fibroblasts. Mean ± SD (three clones assayed at least in quadruplicates). (F) Bright-field images for affected PCH-1298 and PCH-1236 NPCs in standard medium or in 10 mM adenosine-supplemented medium, documenting severely reduced survival. See also Figure S3 and Tables S1 and S3.
Altered Adenosine and Guanine Nucleotides in AMPD2 Mutant Cells
We predicted that cellular uptake of adenosine is necessary for cellular toxicity in AMPD2 mutant cells. We thus treated NPCs with 5-Iodotubercidin to inhibit adenosine uptake and found that it efficiently blocked adenosine toxicity ( Figure S4A ). In contrast, treatment with the adenosine receptor antagonist CSG15943 did not rescue adenosine-mediated toxicity, and the class P1 purinergic receptor agonist 5'-(N-ethylcarboxamido)-adenosine (NECA) was not sufficient to compromise survival ( Figures S4A and S4B) . We conclude that intracellular accumulation of adenosine and derived nucleotides-and not activation of purinergic signaling through cognate receptorsunderlies the neurotoxicity.
Because AMPD2 executes AMP deamination, inactivating mutations predict an accumulation of adenosine nucleotides. We measured nucleotide levels in patient fibroblasts treated with 50 mM adenosine (the lowest toxic dose) and found elevated ATP levels, which were more striking in AMPD2 homozygous mutant cells compared with heterozygous control cells (Figure 4A) . As expected by the inability to deaminate AMP to IMP, there was also a corresponding decrease in guanine nucleotides, which was again more striking in homozygous mutant cells ( Figure 4B) . The results were similar in NPCs cultured with 10 mM adenosine for 5 hr (a time before compromised viability; Figure S4C) . Patient NPCs showed a slight increase in adenosine nucleotides-most notably for ATP ( Figure 4C )-and showed a dramatic reduction in guanine nucleotides-most remarkable Figure S4 and Tables S4 and S5. for GTP-which was reduced by half ( Figure 4D ). These demonstrate that patient cells show adenosine-dependent accumulation of specific adenosine nucleotides and depletion of guanine nucleotides.
De Novo Purine Biosynthesis Is Inhibited in AMPD2 Mutant NPCs
The previous results led us to question why guanine nucleotide levels were reduced only in the presence of exogenous adenosine. In order to assess metabolic profiles more completely, we developed a quantitative mass spectroscopy panel of 140 metabolites (Table S4 ) and tested in unaffected and affected NPCs untreated and treated with two different adenosine concentrations. Adenosine itself, despite addition to the culture media, remained below detectable level, suggesting efficient cellular processing. Many of the analyzed metabolites responded to adenosine treatment similarly in unaffected and affected cells, probably reflecting shared metabolism. However, in accordance with HPLC data, adenosine nucleotide pools were increased slightly, and guanine nucleotide pools were notably decreased in homozygous mutant NPCs ( Figures 4E and S4D and Table S5 ).
Purine nucleotides can exert inhibitory feedback on the de novo pathway by inhibiting phosphoribosyl pyrophosphate (PRPP) synthetase and PRPP amidotransferase (Watts, 1983) . We thus considered whether the accumulated adenosine nucleotides might additionally inhibit de novo purine biosynthesis, which could explain why adenosine treatment reduces guanine nucleotide levels. Several lines of evidence support this model. First, IMP was one of the most reduced compounds in affected NPCs compared with unaffected NPCs, suggesting a failure of the de novo synthesis pathway to generate IMP. Second, IMP should theoretically be salvaged from hypoxanthine and PRPP by the HGPRT enzyme ( Figure 3A) . Despite the presence of hypoxanthine in the culture media, IMP was not replenished and cell growth was restricted, suggesting that PRPP, which is synthesized by PRPP synthetase in the first step of the de novo pathway, is in limiting amounts. Third, 5-Aminoimidazole-4-carboxamide riboside (AICAr, i.e., dephosphorylated AICAR), an intermediate of de novo synthesis, was more severely reduced in affected NPCs than in unaffected NPCs treated with adenosine ( Figure S4E ). Finally, genome-wide expression profiles were compared with and without treatment. Despite a few notable alterations, suggesting mostly acute biochemical and/or posttranscriptional derangements, there was an increase in IMPDH2 levels ( Figures S5A-S5C) , which is known to increase upon guanine nucleotide depletion to support conversion of IMP to GMP (Escobar-Henriques and Daignan-Fornier, 2001 ).
Whereas the activity of de novo purine biosynthesis enzymes is high in proliferating cells such as NPCs, it is much lower in postmitotic cells in general and in adult mammalian brain in particular (Watts, 1983) . We predicted that, if feedback inhibition contributes to the phenotype in proliferating NPCs, postmitotic neurons might be impervious to adenosine treatment. Both control-and patient-derived NPCs were induced toward neuronal differentiation and acquired indistinguishable axon-and dendrite-like structures ( Figure S4F ). Exposure to adenosine in the medium had just a slight effect on survival that was not distinguishable from the effect in control cells at either 15 or 30 day time points (Figure S4G) . Together, the data suggest that blockage of de novo purine nucleotides contributes to the cellular toxicity and guanine nucleotide depletion observed in patient cells.
AMP Deaminase Deficiency Associates with Altered Nucleotide Levels and Degeneration in Brain
In order to determine whether these alterations in nucleotide levels are apparent in intact brain, we studied Ampd2 and Ampd3 knockout (KO) mice Toyama et al., 2012) . The absence of histological phenotype in Ampd2 KO brain ( Figure 5A ) and the coexpression of Ampd2 and Ampd3 in embryonic and postnatal mouse brains, both contributing equally to brain AMP deaminase activity ( Figures 5B and 5C ), prompted us to test for functional redundancy by generating Ampd2 and Ampd3 double-knockout mice (DKO), which were born in the expected Mendelian ratio. Early after birth, DKOs were distinguishable from wild-type (WT) littermates by slightly reduced body weight and severely shortened lifespan limited to 2 or 3 weeks ( Figure 5D ). Besides the slightly reduced brain size, which is consistent with the body size reduction, Ampd2/3 DKO mice brains showed little evidence of the characteristic neuronal loss observed in AMPD2 mutant patients. After P14, we observed a neurodegenerative phenotype mostly affecting the CA3 pyramidal neurons in the hippocampus and some sparse pyknotic cells all over the cortex and the cerebellum ( Figure 5E ), which is associated with behavioral gait disturbance (Movie S1). Investigation of nucleotide levels in these brains at 2 weeks demonstrated a 25% increase in ATP nucleotide levels and a 33% decrease in GTP levels in DKO compared to WT ( Figure 5F ). These results indicate partial genetic redundancy for Ampd2 and Ampd3 in the mouse brain and support a conserved role for AMP deaminase activity in neuroprotection through adenosine nucleotide metabolism and/or maintenance of the guanine nucleotide pool.
AICAr Treatment Rescues Adenosine-Mediated Toxicity in Mutant Cells
The previous data suggest accumulation of adenosine and depletion of guanine nucleotides but did not distinguish relative importance in neurotoxicity. We reasoned that exogenous application of AICAr should allow us to distinguish these because this would bypass a block in de novo synthesis toward guanine nucleotides but only further exacerbate accumulation of adenosine nucleotides through the conversion of IMP to AMP. AICAr is bioavailable to cultured cells and is converted to AICAR through adenosine kinase ( Figure 6A ). The growth phenotype of amd1 yeast was almost completely rescued with increasing AICAr concentrations ( Figure 6B ), suggesting impaired de novo synthesis as a major defect.
We next examined whether patient NPCs might respond similarly to AICAr treatments. However, because AICAr can compete with adenosine for internalization mediated by nucleoside transporters (Gadalla et al., 2004) , we designed a timed protocol ( Figure 6C ). First, we treated patient-derived NPCs with adenosine for 7 hr, followed by washout and culture with standard media for an additional 17 hr. With this protocol, survival of AMPD2 mutant NPCs was similar to cells under continued exposure to adenosine, suggesting lingering toxicity of adenosine. When the media were instead supplemented with AICAr, we noted concentration-dependent rescued viability ( Figure 6D ). Concurrently, following the AICAr protocol, guanine nucleotide levels were restored to near-normal levels ( Figure 6E) , and the genome-wide expression profile demonstrated partial restoration of the IMPDH2 level ( Figure S5C and Table S6 ), suggesting relief of cellular stress.
AMP protein kinase (AMPK) activation is a well-documented effect of AICAr, which was also observed in affected NPCs (Figure S5D) . However, substituting AICAr with Metformin, an AMPK activator that does not directly feed into de novo purine synthesis, failed to rescue adenosine-mediated toxicity ( Figure S5E ), excluding AMPK activation as a rescue mechanism. This, together with confirmation by mass spectroscopy that IMP is significantly restored by AICAr treatment (Figure 6F ), supports de novo purine synthesis as the major target for guanine nucleotide replenishment in AMPD2 mutant cells. (F) Whole-brain nucleotide levels in P14 brains from the four genotypes. ATP levels were significantly increased (26%), and GTP levels were significantly decreased (33%) in Ampd2/3 DKO. Mean ± SD of three replicates. See also Movie S1.
Translation Initiation Is Blocked in AMP Deaminase-Deficient Cells Because the established PCH genes implicate defective protein synthesis and because GTP is the main energy source in protein synthesis, we considered that GTP depletion could impair protein synthesis in AMPD2 mutant PCH patients. Protein synthesis can be assessed at a global level using [35]S-methionine metabolic labeling, which showed a severe defect in patient-derived NPCs following adenosine treatment ( Figure 7A ). This finding was confirmed in the amd1 yeast strain, which showed a (E) Percentage of adenosine or guanine nucleotide levels measured by HPLC in affected NPCs, cultured in adenosine for 7 hr followed by standard medium (NBF) or AICAr 500 mM. Data are compared to 7 hr adenosine + 7h standard medium to minimize the contamination from non-viable NPCs in longer cultures. GMP was nondetectable under all conditions and is thus not shown. Mean ± SD for three clones derived from PCH-1298 and PCH-1236 family affected NPCs. **p < 0.005; Student's t test. (F) Graphical representation of LC-MS/MS data. Concentrations were used to calculate the FC of each metabolite in 10 mM adenosine+standard medium (NBF) (x axis) or 10 mM adenosine+500 mM AICAr (y axis) versus NBF. Average log 2 (FC) for two affected (A) clones from each family PCH-1298 (left) and family PCH-1236 (right). Dashed lines indicate arbitrarily defined correlation threshold. Green and red dots indicate metabolites outside the threshold limits that significantly increase (green) or decrease (red) with AICAr. Guanine nucleotides and IMP are significantly higher in affected NPCs that receive AICAr for 7 hr after adenosine challenge. Metabolites outside the graph scale are not represented (i.e., AICAr). See also Figure S5 and Table S6. decrease of $40% incorporation in acid-insoluble material-a defect completely rescued in a time-dependent fashion with the addition of AICAr in the culture media ( Figure 7B) .
In order to understand this mechanism, we analyzed polyribosome profiles from amd1 and WT strains and found a decrease in the relative amount of actively translating ribosomes (considered as the polyribosome) in the amd1 mutant ( Figure 7C ). The decreasing ratio of polyribosome over monosome (80S peak) in the mutant cells (2.9 and 1.7 for WT and amd1 strains, respectively) suggested a defect in protein translation initiation, as has been documented for eIF2 (eukaryotic translation initiation factor 2) GTP-dependent activation (Foiani et al., 1991) or guanine-nucleotide-depleted cells caused by GMP synthase mutation (Iglesias-Gato et al., 2011) . As a comparison, we evaluated a SEN2 mutant encoding a highly conserved member of the tRNA splicing endonuclease (SEN) complex in yeast, which is orthologous to the human TSEN2 gene and mutated in PCH type 2 (MIM: 608753). We found that the temperature-sensitive mutant sen2-41, which affects tRNA splicing (Yoshihisa et al., 2003) , also showed a pronounced decrease in [35]S-methionine metabolic labeling at a nonpermissive temperature ( Figure 7D ), suggesting the protein translation defect as a common mechanism in PCH.
DISCUSSION
Neuronal Vulnerability in AMPD2 Mutants
Adenosine toxicity is a well-recognized consequence of metabolic derangements and includes a number of downstream consequences such as pyrimidine/purine starvation and defects in methylation (Archer et al., 1985) . Our study demonstrates that neural cells deficient in AMPD activity are exquisitely sensitive to adenosine, which is generated in neural tissue by physiological processes such as active methylation and synaptic activity (Rathbone et al., 1999) . The vulnerability of AMPD2 mutant neurons to physiological levels of adenosine, mediating cellular growth restriction followed by cell death, is likely a consequence of guanine nucleotide depletion. Why do humans show specific vulnerabilities of brainstem structures to AMPD2 mutations? This may reflect regional differences in expression of other AMPD paralogs. Indeed, although AMPD2 and AMPD3 are coexpressed in the developing human cerebral cortex, AMPD2 is predominant in the cerebellum ( Figure S2A ). This, however, does not apply for the mouse brain, in which the two paralogs-present in cortex and cerebellum-contribute equally to brain AMP deaminase activity. Accordingly, we only observe neuronal vulnerability, resulting in ataxia and cell loss, when both Ampd2 and Ampd3 are deleted in mice. This is reminiscent of HPRT deficiency, which leads to Lesch-Nyhan syndrome in humans but to which mice show no consequence unless additional purine metabolism enzymes are pharmacologically inhibited (Wu and Melton, 1993) . Thus, although the simplest interpretation is that vulnerability to AMPD2 mutations is uncovered when AMPD3 compensatory effect is lacking, there may be additional buffering of purine metabolism vulnerability in mice.
Protein Translation Impairment and Neurodegeneration
Known mutations in a wide range of animal models and human disorders suggest misregulation of protein translation as a pathogenic mechanism of neurodegeneration. In the sticky mouse, neurodegeneration is caused by the mutation of an aminoacyl-tRNA synthetase, which disrupts translation fidelity and causes accumulation of misfolded proteins (Lee et al., 2006) . Mutations in the protein synthesis factor Eef1a2 cause neurodegeneration in the Wasted mouse, presumably due to a tissue-specific block of protein translation (Scheper et al., 2007) . Similarly, in humans, the five EIF2B genes that encode translation initiation factors are each mutated in childhood ataxia with central nervous system hypomyelinization (CACH, MIM: 603896). In PCH, the most common mutations fall in three of the four known subunits of tRNA endonuclease complex (TSEN54, TSEN34, and TSEN2) (Budde et al., 2008) , which presumably affect tRNA processing and downstream protein translation but are not yet demonstrated in patient cells. Although we did not fully explore other global consequences of GTP depletion such as on RNA or DNA synthesis (Cohen et al., 1981) , our identification of similar protein synthesis defects in AMP deaminase-deficient cells and in yeast mutant for sen2 (TSEN2 ortholog) suggests that reduced protein synthesis may be a common pathogenic mechanism for neurodegeneration in PCH.
Enhancement of De Novo Purine Biosynthesis as Therapeutic Target
We identified deficiency in guanine nucleotides as central to the AMPD2 pathogenesis and linked this to defective protein synthesis. There are other requirements for guanine nucleotides to meet cellular energy and signaling demands, including G protein signaling and microtubule polymerization, which we do not evaluate here. Deficiency of guanine nucleotides as central to the pathogenesis was supported by AICAr treatment, which rescues GTP depletion, protein synthesis block, and cell survival phenotypes. Might this serve as a potential treatment in patients? AICAr is proven to be beneficial for exercise endurance by means of AMPK activation, the master regulator of cellular energy metabolism (Narkar et al., 2008) . However, by targeting the same pathway, AICAr can inhibit axon growth in mouse cultured cortical neurons (Williams et al., 2011 ). AICAr's effects on nucleotide metabolism are disparate, showing biphasic effects on cell survival by inhibition of pyrimidine nucleotide biosynthesis (Thomas et al., 1981) . Therefore, if AICAr is to be used therapeutically, thorough evaluation of effective nontoxic dosage would be required. Although AICAr's potential as therapeutic treatment remains to be studied, enhancing de novo purine biosynthesis might be efficient in the treatment of PCH type 9.
EXPERIMENTAL PROCEDURES
Patient Recruitment
Patients were enrolled and sampled according to standard local practice in approved human subject protocols at the University of California.
Exome Sequencing DNA was extracted from peripheral blood leukocytes by salt extraction. Exon capture, sequencing, variant calling, and filtering were performed as previously described (Dixon-Salazar et al., 2012) . For specific details, see Extended Experimental Procedures.
Yeast Strains and Culture Conditions
To generate the S. cerevisiae amd1 mutant strain, the AMD1/YML035C ORF was replaced by PCR-based gene targeting with the hphNT1 marker (Janke et al., 2004) in the haploid reference strain BY4741. Yeast cultures were grown as described (Saint-Marc et al., 2009 ). For specific details, see Extended Experimental Procedures.
Fibroblast Culture, iPSC, and NPC Generation Fibroblasts were generated from unaffected and affected dermal biopsies explants. iPSCs, neural progenitor cells, and neurons were obtained as previously described (Chambers et al., 2009; Okita et al., 2011) . For specific details, see Extended Experimental Procedures.
Mouse
Animal use followed NIH guidelines and was approved by IACUC at the University of California, San Diego. Ampd2 (À/À) mice were previously generated , and Ampd3 (À/À) were either generated by us using embryonic stem (ES) cell clone EPD0043_3_B02 generated by the Wellcome Trust Sanger Institute (https://www.komp.org/) or from previous publication .
Growth Curve and Cell Survival
Modified MTT method (Carmichael et al., 1987) was used for growth curve and survival analysis, which is detailed in the Extended Experimental Procedures.
AMP Deaminase Activity Assay AMP deaminase activity was performed as previously described (Kirkwood et al., 2012) with minor modifications detailed in the Extended Experimental Procedures.
Nucleotide Analysis by HPLC Nucleotide extraction was performed as previously described (Fairbanks et al., 2002) , and nucleotides were analyzed by high-performance liquid chromatography (HPLC). For specific details, see Extended Experimental Procedures.
Liquid Chromatography-Tandem Mass Spectrometry Metabolites were extracted with 80:20/0.1% Methanol:Water/Formic acid precooled to À80 C and 13 C-Labeled E. coli extract as an internal standard.
Chromatographic separation was achieved using a UFLC XR HPLC (Shimadzu), and compounds were detected and quantified on an AB SCIEX Qtrap 5500 mass spectrometer (AB SCIEX). For specific details, see Extended Experimental Procedures.
Polysome Profiling
Yeast extracts were prepared as described (Esposito et al., 2010) . Typically, 10 OD260 of nucleic acid were loaded onto an 11 ml linear sucrose gradient (10 to 50% w/v) and centrifuged using SW40Ti rotor (Beckman) at 39,000 rpm for 160 min at 4 C. Sample tubes were loaded on a tube piercer after priming the system with 55% sucrose, and a flow rate of 800 ml/min was set on the peristaltic pump. Absorbance at 254 was monitored using an Econo UV monitor (BioRad), and data were collected and analyzed with the WinDaq software (DATAQ Instruments). 
ACCESSION NUMBERS
